Jennifer J.D. Morrissette, PhD
Associate Professor of Clinical Pathology and Laboratory Medicine
Clinical Director, Center for Personalized Diagnostics
University of Pennsylvania Perelman School of Medicine
Contact InformationDepartment of Pathology and Laboratory Medicine
3020 Market Street, Suite 220
Philadelphia, PA 19104
Office: 215-898-5578
Fax: 215-898-9817
Email: jennifer.morrissette@uphs.upenn.edu
Specialty Division
Precision and Computational Diagnostics
Education
B.S. (Molecular Biology), State University of New York at Buffalo, 1986
Ph.D. (Molecular Genetics), State University of New York at Buffalo, 1992
Specialty Certification
American Board of Medical Genetics, Clinical Molecular Genetic Diagnostics, 2002
American Board of Medical Genetics, Clinical Cytogenetics, 2002
New York State Certificate of Qualification,
Cytogenetics and Molecular Genetic Diagnostics, 2004
Postgraduate Training
Postdoctoral Fellow, Molecular Genetics, Department of Pathology, Harvard Medical School, Boston MA, 1992-1997
Fellow in Genetics, The Children’s Hospital of Philadelphia, Philadelphia, PA, 1998-2002
Awards and Honors
Mark Diamond Initiative Award, Department of Biological Sciences, State University of New York at Buffalo, 1990
NIH Intramural Research Training Award fellowship, 1992-1993
Pathobiology of Cancer: The Edward A. Smuckler Memorial Workshop, Keystone Colorado, American Association of Cancer Research, 1992
American Social Health Association/Burroughs Wellcome Fund Research Fellowship, 1994-1996
American Association of Cancer Research Fellowship, 1996-1997
General Clinical Research Center (GCRC). Children’s Hospital of Philadelphia, Investigator, 2001-2005
Foerderer Fund for Excellence, Molecular and Cytogenetic Analysis of Autism, 2003-2004
Peter C. Nowell Award in Pathology, University of Pennsylvania, 2013
Memberships and Professional Organizations
American Society Human Genetics, 1998 - Present
Philadelphia Genetics Group, 2004 - 2018
American College of Medical Genetics, 2005 - Present
American Cytogenetics Conference, 2006 - Present
Association of Molecular Pathology, 2011 - Present
American Society for Clinical Pathology (ASCP) Immuno-Oncology Working Group, 2018 - Present
International Federation of Clinical Chemistry and Laboratory Medicine, 2019 - Present
Web Links
Selected Publications
Genomic landscape of metastatic breast cancer identifies preferentially dysregulated pathways and targets.
Paul MR, Pan TC, Pant DK, Shih NN, Chen Y, Harvey KL, Solomon A, Lieberman D, Morrissette JJ, Soucier-Ernst D, Goodman NG, Stavropoulos SW, Maxwell KN, Clark C, Belka GK, Feldman M, DeMichele A, Chodosh LA., J Clin Invest 130(): 4252-4265, 2020, PMID:32657779
Mutational Analysis Reinforces the Diagnosis of Nodal Marginal Zone Lymphoma With Robust PD1-positive T-Cell Hyperplasia
Hurwitz SN, Caponetti GC, Smith L, Qualtieri J, Morrissette JJD, Lee WS, Frank DM, Bagg A., Am J Surg Pathol., 2020, PMID:32520760
Mutational Analysis Reinforces the Diagnosis of Nodal Marginal Zone Lymphoma With Robust PD1-positive T-Cell Hyperplasia
Hurwitz SN, Caponetti GC, Smith L, Qualtieri J, Morrissette JJD, Lee WS, Frank DM, Bagg A., Am J Surg Pathol., 2020, PMID:32520760
EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma
Struve N, Binder ZA, Stead LF, Brend T, Bagley SJ, Faulkner C, Ott L, Müller-Goebel J, Weik AS, Hoffer K, Krug L, Rieckmann T, Bußmann L, Henze M, Morrissette JJD, Kurian KM, Schüller U, Petersen C, Rothkamm K, O Rourke DM, Short SC, Kriegs M., Oncogene 39(): 3041-3055, 2020, PMID:32066879
Clinical Utility of Plasma Cell-Free DNA in Adult Patients with Newly Diagnosed Glioblastoma: A Pilot Prospective Study.
Bagley SJ, Nabavizadeh SA, Mays JJ, Till JE, Ware JB, Levy S, Sarchiapone W, Hussain J, Prior T, Guiry S, Christensen T, Yee SS, Nasrallah MP, Morrissette JJD, Binder ZA, O'Rourke DM, Cucchiara AJ, Brem S, Desai AS, Carpenter EL., Clin Cancer Res. 26(): 397-407, 2020, PMID:31666247
Clinical Activity of the EGFR Tyrosine Kinase Inhibitor Osimertinib in EGFR-mutant Glioblastoma
Makhlin I, Salinas RD, Zhang D, Jacob F, Ming G-L, Song H, Saxena D, Dorsey JF, Nasrallah MP, Morrissette JJD, Binder ZA, O'Rourke DM, Desai AS, Brem S, Bagley SJ, CNS Oncol. 8(): , 2019, PMID:31769726
Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma.
Hoffman DI, Abdullah KG, McCoskey M, Binder ZA, O'Rourke DM, Desai AS, Nasrallah MP, Bigdeli A, Morrissette JJD, Brem S, Bagley SJ., Journal of Neurooncology 145(2): 321-328, 2019, PMID:31542863
Clinical Utility of Plasma Cell-Free DNA in Adult Patients with Newly Diagnosed Glioblastoma: A Pilot Prospective Study
Bagley SJ, Nabavizadeh SA, Mays JJ, Till JE, Ware JB, Levy S, Sarchiapone W, Hussain J, Prior T, Guiry S, Christensen T, Yee SS, Nasrallah MP, Morrissette JJD, Binder ZA, O'Rourke DM, Cucchiara AJ, Brem S, Desai AS, Carpenter EL., Clinical Cancer Research, 2019
Clinical Utility of Plasma Cell-Free DNA in Adult Patients with Newly Diagnosed Glioblastoma: A Pilot Prospective Study.
Bagley SJ, Nabavizadeh SA, Mays JJ, Till JE, Ware JB, Levy S, Sarchiapone W, Hussain J, Prior T, Guiry S, Christensen T, Yee SS, Nasrallah MP, Morrissette JJD, Binder ZA, O'Rourke DM, Cucchiara AJ, Brem S, Desai AS, Carpenter EL, Clinical Cancer Research 26(): 397-407, 2019, PMID:31666247
Longitudinal targeted next-generation sequencing in a patient with acute myeloid leukaemia
Velu, PD, Perl, AE, Luger, SM, Bagg, A, Morrissette, JJD, British Journal of Haematology 186(6): 801, 2019
